NeuroMab™ Anti-IGF1R BBB Shuttle Antibody, Clone 9G4

Figure 1 Study of the antitumor activity of the mouse antibody 7C10 in an in vivo tumor cell xenograft model.

Figure 1 A549 lung non-small cell tumor model. In these three models, treatments were given twice weekly at a rate of 250 μg/dose/mouse. Curves 7G3, EC2 and 9G4 respectively correspond to the three murine IgGl isotypes used as experimental controls in each model.

Figure 2 Study of the antitumor effect of MAb 7C10 compared with vinorelbine and the synergistic effect of the two compounds on the growth of the A549 line in vivo.

Figure 3 Comparative activity of MAbs αIR3, 7C10 and 1H7 on MCF-7 cells induced IGF-2 proliferation.

Figure 4 Comparison of murine 7C10 and chimeric C7C10 MAbs for inhibition of IGF1 proliferation in MCF-7 cells in vitro. Antibody 9G4 is a murine IgGl isotype used as an experimental control.

Figure 5 Antitumor activity of the 7C10 antibody in the orthotopic model A549.

Figure 6 Comparison of the effects of antibodies 7C10 and 7H2HM on the growth of A549 cells in vitro.

Figure 7 Effect of co-administration of MAB 7C10 and 225 on tumor A549 growth in vivo.

Figure 8 Effect of co-administration of MAB 7C10 and 225 on survival of mice orthotopically implanted with A549 cells.

Figure 9 On unlabeled ligand (IGF-I) or antibody (7C10, h7C10 , 1H7, 9G4).

Figure 10 Immunocapture of R-/IR-A cell lysate Hybrid-RA in Maxisorb plates coated with 83-7 antibody in the absence or presence of increasing concentrations of unlabeled ligand (IGF-I) Down by 125I-IGF-I binding or antibodies (7C10, h7C10, 1H7, 9G4).

Figure 11 Immunocapture of R-/IR-B cell lysate Hybrid-RB in Maxisorb plates coated with 83-7 antibody in the absence or presence of increasing concentrations of unlabeled ligand (IGF-I) Down by 125I-IGF-I binding or antibodies (7C10, h7C10, 1H7, 9G4).